Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice

Journal of Lipid Research

Volumn 54, Issue 10, 2013, Pages 2647-2657

  Bell III, Thomas A ^a   Graham, Mark J ^a   Lee, Richard G ^a   Mullick, Adam E ^a   Fu, Wuxia ^a   Norris, Dan ^a   Crooke, Rosanne M ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Cardiovascular disease; Cholesteryl ester transfer protein; Lipoprotein metabolism; Low density lipoprotein

Indexed keywords

ANACETRAPIB; ANTISENSE OLIGONUCLEOTIDE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CETP GENE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; GENE EXPRESSION; HYPERLIPIDEMIA; LIPID ANALYSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE CHOLESTEROL TRANSPORT; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASE; CHOLESTERYL ESTER TRANSFER PROTEIN; LIPOPROTEIN METABOLISM; LOW DENSITY LIPOPROTEIN;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA; BIOLOGICAL TRANSPORT; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; COMBINED MODALITY THERAPY; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; LIVER; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; OLIGONUCLEOTIDES, ANTISENSE; OXAZOLIDINONES; RECEPTORS, LDL; RNA INTERFERENCE; TRIGLYCERIDES;

EID: 84884139889     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M036509     Document Type: Article

References (56)

1. Heron, M. 2007. Deaths: leading causes for 2004. Natl. Vital Stat. Rep. 56: 1-95.
2. Baigent, C., A. Keech, P. M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, et al. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366: 1267-1278.
3. Grundy, S. M., J. I. Cleeman, C. N. Merz, H. B. Brewer, L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith, and N. J. Stone. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler. Thromb. Vasc. Biol. 24: e149 - e161.
4. Charles, M. A., and J. P. Kane. 2012. New molecular insights into CETP structure and function: a review. J. Lipid Res. 53: 1451-1458.
5. Brown, M. L., A. Inazu, C. B. Hesler, L. B. Agellon, C. Mann, M. E. Whitlock, Y. L. Marcel, R. W. Milne, J. Koizumi, and H. Mabuchi. 1989. Molecular basis of loipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature. 342: 448-451.
6. Yamashita, S., D. Y. Hui, D. L. Sprecher, Y. Matsuzawa, N. Sakai, S. Tarui, D. Kaplan, J. R. Wetterau, and J. A. Harmony. 1990. Total deficiency of plasma cholesteryl ester transfer protein in subjects homozygous and heterozygous for the intron 14 splicing defect. Biochem. Biophys. Res. Commun. 170: 1346-1351.
7. Inazu, A., M. L. Brown, C. B. Hesler, L. B. Agellon, J. Koizumi, K. Takata, Y. Maruhama, H. Mabuchi, and A. R. Tall. 1990. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323: 1234-1238.
8. Zhong, S., D. S. Sharp, J. S. Grove, C. Bruce, K. Yano, and A. R. Tall. 1996. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97: 2917-2923.
9. Moriyama, Y., T. Okamura, A. Inazu, M. Doi, H. Iso, Y. Mouri, Y. Ishikawa, H. Suzuki, M. Iida, J. Koizumi, et al. 1998. A low prevalence of coronary heart disease among subjects with increased high density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev. Med. 27: 659-667.
10. Thompson, A., E. Di Angelantonio, N. Sarwar, S. Erqou, D. Saleheen, R. P. Dullaart, B. Keavney, Z. Ye, and J. Danesh. 2008. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 299: 2777-2788.
11. Ridker, P. M., G. Pare, A. N. Parker, R. Y. Zee, J. P. Miletich, and D. I. Chasman. 2009. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet. 2: 26-33.
12. Brousseau, M. E., E. J. Schaefer, M. L. Wolfe, L. T. Bloedon, A. G. Digenio, R. W. Clark, J. P. Mancuso, and D. J. Rader. 2004. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350: 1505-1515.
13. Brousseau, M. E., M. R. Diffenderfer, J. S. Millar, C. Nartsupha, B. F. Asztalos, F. K. Welty, M. L. Wolfe, M. Rudling, I. Bjorkhm, B. Angelin, et al. 2005. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler. Thromb. Vasc. Biol. 25: 1057-1064.
14. Barter, P. J., M. Caulfield, M. Eriksson, S. M. Grundy, J. J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J. C. Tardif, D. D. Waters, et al. 2007. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357: 2109-2122.
15. Barter, P. 2009. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am. J. Cardiol. 104 (10 Suppl.) : 10E - 15E.
16. Schwartz, G. G., A. G. Olsson, M. Abt, C. M. Ballantyne, P. J. Barter, J. Brumm, B. R. Chaitman, I. M. Holme, D. Kallend, L. A. Leiter, E. Leitersdorf, et al. 2012. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367: 2089-2099.
17. Kuivenhoven, J. A., G. J. de Grooth, H. Kawamura, A. H. Klerkx, F. Wilhelm, M. D. Trip, and J. J. Kastelein. 2005. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am. J. Cardiol. 95: 1085-1088.
18. Stein, E. A., E. M. Roth, J. M. Rhyne, T. Burgess, D. Kallend, and J. G. Robinson. 2010. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur. Heart J. 31: 480-488.
19. Hooper, A. J., and J. R. Burnett. 2012. Dalcetrapib, a cholesteryl ester transfer protein modulator. Expert Opin. Investig. Drugs. 21: 1427-1432.
20. Bloomfield, D., G. L. Carlson, A. Sapre, D. Tribble, J. M. McKenney, T. W. Littlejohn 3rd, C. M. Sisk, Y. Mitchel, and R. C. Pasternak. 2009. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am. Heart J. 157: 352-360.e2.
21. Nicholls, S. J., H. B. Brewer, J. J. Kastelein, K. A. Krueger, M. D. Wang, M. Shao, B. Hu, E. McErlean, and S. E. Nissen. 2011. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 306: 2099-2109.
22. Ranalletta, M., K. K. Bierilo, Y. Chen, D. Milot, Q. Chen, E. Tung, C. Houde, N. H. Elowe, M. Garcia-Calvo, G. Porter, et al. 2010. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J. Lipid Res. 51: 2739-2752.
23. Ravikumar, V. T., M. Andrade, R. L. Carty, A. Dan, and S. Barone. 2006. Development of siRNA for therapeutics: efficient synthesis of phosphorothioate RNA utilizing phenylacetyl disulfide (PADS). Bioorg. Med. Chem. Lett. 16: 2513-2517.
24. Smith, C. J., A. Ali, M. L. Hammond, H. Li, Z. Lu, J. Napolitano, G. E. Taylor, C. F. Thompson, M. S. Anderson, Y. Chen, et al. 2011. Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib. J. Med. Chem. 54: 4880-4895.
25. Agellon, L. B., A. Walsh, T. Hayek, P. Moulin, X. C. Jiang, S. A. Shelanski, J. L. Breslow, and A. R. Tall. 1991. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J. Biol. Chem. 266: 10796-10801.
26. Aviram, M. 1983. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem. Med. 30: 111-118.
27. Malekzadeh, A., V. de Groot, H. Beckerman, B. W. van Oosten, M. A. Blankenstein, and C. Teunissen. 2012. Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. Methods. 56: 508-513.
28. Valenta, D. T., N. Ogier, G. Bradshaw, A. S. Black, D. J. Bonnet, L. Lagrost, L. K. Curtiss, and C. M. Desrumaux. 2006. Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression. Arterioscler. Thromb. Vasc. Biol. 26: 1572-1578.
29. Lagor, W. R., R. J. Brown, S. A. Toh, J. S. Millar, I. V. Fuki, M. de la Llera-Moya, T. Yuen, G. Rothblat, J. T. Billheimer, and D. J. Rader. 2009. Overexpression of apolipoprotein F reduces HDL cholesterol levels in vivo. Arterioscler. Thromb. Vasc. Biol.. 29: 40-46.
30. Zhang, Y., I. Zanotti, M. P. Reilly, J. M. Glick, G. H. Rothblat, and D. J. Rader. 2003. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 108: 661-663.
31. Temel, R. E., J. K. Sawyer, L. Yu, C. Lord, C. Degirolamo, A. McDaniel, S. Marshall, N. Wang, R. Shah, L. L. Rudel, et al. 2010. Biliary sterol secretion is not required for macrophage reverse cholesterol transport. Cell Metab. 12: 96-102.
32. Bligh, E. G., and W. J. Dyer. 1959. A rapid method for total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917.
33. Millar, J. S., D. A. Cromley, M. G. McCoy, D. J. Rader, and J. T. Billheimer. 2005. Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with triton wr-1339. J. Lipid Res. 46: 2023-2028.
34. Carr, T. P., C. J. Andresen, and L. L. Rudel. 1993. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin. Biochem. 26: 39-42.
35. Tangirala, R. K., E. M. Rubin, and W. Palinski. 1995. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid Res. 36: 2320-2328.
36. Hoekstra, M., T. J. Van Berkel, and M. Van Eck. 2010. Scavenger receptor BI: a multi-purpose player in cholesterol and steroid metabolism. World J. Gastroenterol. 16: 5916-5924.
37. Herz, J., and D. K. Strickland. 2001. LRP: a multifunctional scavenger and signaling receptor. J. Clin. Invest. 108: 779-784.
38. Mizuno, Y., R. F. Jacob, and R. P. Mason. 2011. Inflammation and the development of atherosclerosis. J. Atheroscler. Thromb. 18: 351-358.
39. Marcel, Y. L., R. McPherson, M. Hogue, H. Czarnecka, Z. Zawadzki, P. K. Weech, M. E. Whitlock, A. R. Tall, and R. W. Milne. 1990. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. J. Clin. Invest. 85: 10-17.
40. Krishna, R., A. J. Bergman, B. Jin, M. Fallon, J. Cote, P. Van Hoydonck, T. Laethem, I. N. Gendrano 3rd, K. Van Dyck, D. Hilliard, et al. 2008. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin. Pharmacol. Ther. 84: 679-683.
41. Tohyama, J., J. T. Billheimer, I. V. Fuki, G. H. Rothblat, D. J. Rader, and J. S. Millar. 2009. Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice. Atherosclerosis. 204: 418-423.
42. Briand, F., Q. Thieblemont, A. André, K. Ouguerram, and T. Sulpice. 2011. CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice. Clin. Transl. Sci. 4: 414-420.
43. Briand, F., Q. Thieblemont, E. Muzotte, and T. Sulpice. 2013. Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination WITH the LDLlowering drug berberine in dyslipidemic hamsters. Arterioscler. Thromb. Vasc. Biol. 33: 13-23.
44. Niesor, E. J., C. Magg, N. Ogawa, H. Okamoto, E. von der Mark, H. Matile, G. Schmid, R. G. Clerc, E. Chaput, D. Blum-Kaelin, et al. 2010. Modulating cholesteryl ester transfer protein activity maintains efficient pre- HDL formation and increases reverse cholesterol transport. J. Lipid Res. 51: 3443-3454.
45. Castro-Perez, J., F. Briand, K. Gagen, S. P. Wang, Y. Chen, D. G. McLaren, V. Shah, R. J. Vreeken, T. Hankemeier, T. Sulpice, et al. 2011. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. J. Lipid Res. 52: 1965-1973.
46. Plump, A. S., L. Masucci-Magoulas, C. Bruce, C. L. Bisgaier, J. L. Breslow, and A. R. Tall. 1999. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler. Thromb. Vasc. Biol. 19: 1105-1110.
47. Johannsen, T. H., R. Frikke-Schmidt, J. Schou, B. G. Nordestgaard, and A. Tybjærg-Hansen. 2012. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J. Am. Coll. Cardiol. 60: 2041-2048.
48. de Vries, R., B. J. Beusekamp, M. N. Kerstens, A. K. Groen, A. Van Tol, and R. P. Dullaart. 2005. Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes. 54: 3554-3559.
49. Guerin, M., W. Le Goff, E. Duchene, Z. Julia, T. Nguyen, T. Thuren, C. L. Shear, and M. J. Chapman. 2008. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 28: 148-154.
50. Diffenderfer, M. R., M. E. Brousseau, J. S. Millar, P. H. Barrett, C. Nartsupha, P. M. Schaefer, M. L. Wolfe, G. G. Dolnikowski, D. J. Rader, and E. J. Schaefer. 2012. Effects of CETP inhibition on triglyceride- rich lipoprotein composition and apoB-48 metabolism. J. Lipid Res. 53: 1190-1199.
51. Quinet, E., A. Tall, R. Ramakrishnan, and L. Rudel. 1991. Plasma lipid transfer protein as a determinant of the atherogenicity of monkey plasma lipoproteins. J. Clin. Invest. 87: 1559-1566.
52. Westerterp, M., C. C. van der Hoogt, W. de Haan, E. H. Offerman, G. M. Dallinga-Thie, J. W. Jukema, L. M. Havekes, and P. C. Rensen. 2006. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE3-Leiden mice. Arterioscler. Thromb. Vasc. Biol. 26: 2552-2559.
53. Marotti, K. R., C. K. Castle, T. P. Boyle, A. H. Lin, R. W. Murray, and G. W. Melchior. 1993. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 364: 73-75.
54. Sugano, M., N. Makino, S. Sawada, S. Otsuka, M. Watanabe, H. Okamoto, M. Kamada, and A. Mizushima. 1998. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273: 5033-5036.
55. Huang, Z., A. Inazu, A. Nohara, T. Higashikata, and H. Mabuchi. 2002. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin. Sci. (Lond.). 103: 587-594.
56. Morehouse, L. A., E. D. Sugarman, P. A. Bourassa, T. M. Sand, F. Zimetti, F. Gao, G. H. Rothblat, and A. J. Milici. 2007. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J. Lipid Res. 48: 1263-1272.